![\"MRI](\"https:\/\/rtmedical.com.br\/wp-content\/uploads\/2026\/05\/news-katja-pinker-rm-mamaria.jpg\")
Breast MRI is the most sensitive test for breast cancer \u2014 markedly above mammography and ultrasound in high-risk women \u2014 but massive adoption hits three practical walls: exam duration (traditionally 30\u201345 minutes), need for gadolinium contrast, and equipment cost. Pinker and collaborators tackle all three at once.<\/p>\n
Abbreviated MRI (ABBR): more exams in less time<\/h2>\n
Abbreviated breast MRI uses a lean subset of sequences \u2014 typically one pre-contrast T1, an early post-contrast acquisition, and a subtraction sequence \u2014 to cut total duration to 5\u201310 minutes. Studies published in recent years, with strong participation from Pinker’s group, have shown that sensitivity and negative predictive value of the abbreviated protocol stay comparable to the full multiparametric protocol in high-risk populations.<\/p>\n
The practical impact is large. A scanner doing 10 breast MRIs a day under standard protocol can climb to 30\u201340 with ABBR \u2014 while keeping diagnostic quality. For services trying to expand MRI screening in women with genetic risk (BRCA, Li-Fraumeni, family history) or dense breasts, the math becomes viable. As we discussed in our coverage of the PD-L1 radiomics model presented at the same ISMRM 2026<\/a>, quantitative data extracted from these fast acquisitions feed extra layers of prognostic information.<\/p>\n The second pillar of the Pinker agenda is dropping gadolinium. Gadolinium-based contrast is safe in most patients but carries three problems: brain accumulation with repeated use (especially with linear agents), logistical cost (IV access, recovery, adverse events), and contraindications in renal patients. Replacing it with diffusion-weighted sequences (DWI) is the holy grail.<\/p>\n Data from Pinker and other European groups show that DWI with high b-values plus ADC mapping can approach \u2014 though not yet match \u2014 the sensitivity of contrast-enhanced MRI for cancer detection. The path seems to be combining multi-b DWI with AI models trained to identify discriminative patterns. When that matures, breast MRI may run as a mass-screening tool, with no needle and no contrast \u2014 unthinkable five years ago.<\/p>\n The third vector is AI. Pinker is one of the few radiologists fluent in both clinical imaging and radiomics and deep neural networks. Her publications cover automated lesion detection and models that predict molecular features \u2014 estrogen receptor status, HER2, Ki-67, PD-L1 expression \u2014 from breast imaging.<\/p>\nContrast-free MRI: diffusion and the promise of dropping gadolinium<\/h2>\n
AI: from assisted reads to biomarker discovery<\/h2>\n